Use of ADCC-optimized antibodies for treating low-responder patients

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9879089
SERIAL NO

14702143

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESLES ULIS

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bihoreau, Nicolas Orsay, FR 32 250
Bourel, Dominique La Madeleine, FR 29 306
de, Romeuf Christophe Lambersart, FR 42 230
Gaucher, Christine Sequedin, FR 17 75
Jorieux, Sylvie Villeneuve D'Ascq, FR 15 155
Klein, Philippe Lille, FR 88 1668
Nony, Emmanuel Antony, FR 36 246

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 30, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 30, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00